We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Danaher Corporation | NYSE:DHR | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.20 | -0.08% | 246.62 | 247.00 | 244.28 | 246.50 | 3,894,536 | 21:53:28 |
From Apr 2019 to Apr 2024
By Stephen Nakrosis
Danaher Corp. on Monday named Jose-Carlos Gutierrez-Ramos to be SVP and chief scientific officer for the company.
Danaher said prior to joining the company, Dr. Gutierrez-Ramos was the head of Global Drug Discovery and a member of the executive R&D team at AbbVie Inc. Before that, he was president and chief executive of Repertoire Immune Medicines and Synlogic, and before that served in R&D roles at Pfizer Inc. and GlaxoSmithKline PLC among other companies, Danaher said.
Before moving into the private sector, Dr. Gutierrez-Ramos was a tenure track professor at Harvard Medical School in the Department of Genetics and an investigator at The Center for Blood Research, Danaher said.
The company said he will be responsible "for helping define Danaher's science and technology strategy across the organization, including facilitating innovation and further development of scientific and technology talent."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 21, 2020 19:07 ET (00:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Danaher Chart |
1 Month Danaher Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
